Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The broad societal value of pembrolizumab for women's cancer in Canada.

Future oncology (London, England)·2026
Same author

Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.

Health technology assessment (Winchester, England)·2026
Same author

Comment on "Cost Comparisons in NICE Technology Appraisals: An External Assessment Group Perspective" by Marten J. Poley et al.

PharmacoEconomics·2025
Same author

Evaluating the broad societal value of pembrolizumab in women's cancer in Brazil.

Journal of medical economics·2025
Same author

Structured Expert Elicitation to Inform Long-Term Survival Extrapolations in Advanced Renal Cell Carcinoma.

Applied health economics and health policy·2025
Same author

A Matching-Adjusted Indirect Comparison of Guselkumab and Secukinumab in Patients with Psoriatic Arthritis Over 52 Weeks.

Rheumatology and therapy·2025

Related Experiment Video

Updated: Jun 29, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K

Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes.

Rose J Hart1, Fareen Hassan2, Sarah Alulis3

  • 1Lumanity, Sheffield, UK.

Advances in Therapy
|March 30, 2024
PubMed
Summary

Optimizing treatment sequences for immune-mediated disorders like rheumatoid arthritis and ulcerative colitis can significantly reduce patient treatment failures. Early use of the most effective therapies improves outcomes and minimizes failures in immune-mediated diseases.

Keywords:
Ankylosing spondylitisCrohn’s diseaseNon-radiographic axial spondyloarthritisOptimisationPlaque psoriasisPsoriatic arthritisResponseRheumatoid arthritisSequencingUlcerative colitis

More Related Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.7K

Related Experiment Videos

Last Updated: Jun 29, 2025

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

9.5K
Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments
07:46

Microfluidic Co-Culture Models for Dissecting the Immune Response in in vitro Tumor Microenvironments

Published on: April 30, 2021

4.7K

Area of Science:

  • Immunology and Pharmacoepidemiology
  • Health Economics and Outcomes Research

Background:

  • Limited evidence exists on optimal treatment sequencing for immune-mediated disorders.
  • Treatment selection impacts patient outcomes and healthcare system costs.
  • Investigating treatment sequences is crucial for improving care in conditions like ankylosing spondylitis and rheumatoid arthritis.

Purpose of the Study:

  • To model the impact of optimal treatment sequencing on effectiveness and budget reallocation.
  • To analyze treatment sequences for ankylosing spondylitis, Crohn's disease, plaque psoriasis, rheumatoid arthritis, and ulcerative colitis in an Italian setting.
  • To identify best practices for sequencing biological or disease-modifying treatments.

Main Methods:

  • A 3-year state-transition model simulated potential effectiveness improvements and budget considerations.
  • Analyzed sequences of three biological or disease-modifying treatments followed by best supportive care.
  • Utilized published network meta-analyses and real-world data, differentiating between biologic-naïve and experienced populations.

Main Results:

  • Optimal sequences consistently involved using the most efficacious therapies earlier in the treatment pathway.
  • Significant improvements in prescribing practice were identified, particularly for ulcerative colitis.
  • Using top-tier sequences reduced treatment failures by 15.1% with a 1.59% increase in drug costs.

Conclusions:

  • Prioritizing more efficacious treatments earlier in the sequence enhances patient outcomes.
  • Strategic treatment sequencing minimizes treatment failures across various immune-mediated diseases.
  • Optimized sequencing offers a pathway to improved patient care and resource management.